Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer

T Shenkier, L Weir, M Levine, I Olivotto, T Whelan… - Cmaj, 2004 - Can Med Assoc
Objective: To define the optimal treatment for women with stage III or locally advanced breast
cancer (LABC). Evidence: Systematic review of English-language literature retrieved from …

[HTML][HTML] Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

…, M Cobleigh, EA Perez, T Shenkier… - New England journal …, 2007 - Mass Medical Soc
Background In an open-label, randomized, phase 3 trial, we compared the efficacy and
safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against …

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R …

…, K Gill, P Hoskins, R Klasa, KJ Savage, T Shenkier… - Blood, 2007 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a
wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has …

[PDF][PDF] Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma

…, EA Neuwelt, BP O'Neill, E Thiel, T Shenkier… - J Clin …, 2005 - researchgate.net
Standardized guidelines for the baseline evaluation and response assessment of primary
CNS lymphoma (PCNSL) are critical to ensure comparability among clinical trials for newly …

[HTML][HTML] Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel …

…, EA Perez, M Cobleigh, T Shenkier… - Journal of Clinical …, 2008 - ncbi.nlm.nih.gov
Purpose No biomarkers have been identified to predict outcome with the use of an
antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has …

Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors

V Mak, J Hamm, M Chhanabhai, T Shenkier… - Journal of clinical …, 2013 - ascopubs.org
Introduction A number of novel therapies are under investigation in relapsed or refractory
peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We …

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma

…, KJ Savage, LH Sehn, TN Shenkier… - Journal of Clinical …, 2008 - ascopubs.org
Purpose To assess the incidence and predictive factors for development of transformed
lymphoma in a population-based series of patients with follicular lymphoma (FL). Patients and …

[PDF][PDF] Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion …

…, S Martino, BP Findlay, TN Shenkier… - Journal of Clinical …, 2006 - academia.edu
Purpose Aromatase inhibition depletes estrogen levels and may be associated with
accelerated bone resorption. The National Cancer Institute of Canada Clinical Trials Group (NCIC …

[PDF][PDF] Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group

TN Shenkier, JY Blay, BP O'Neill… - Journal of Clinical …, 2005 - researchgate.net
Purpose To describe the demographic and tumor related characteristics and outcomes for
patients with primary T-cell CNS lymphoma (TPCNSL).

[PDF][PDF] International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era

…, RJ Klasa, KJ Savage, TN Shenkier… - Journal of clinical …, 2012 - scholar.archive.org
Purpose The International Prognostic Score (IPS) is the most widely used risk stratification
index for Hodgkin’s lymphoma (HL). It is based on patients treated before 1992 and predicts 5-…